Peptide Initiative

Peptide profile · Hormone Support

Buserelin

A synthetic GnRH agonist that suppresses hormones to help treat prostate cancer, endometriosis, and infertility

Strong human trialsNot FDA approved
2-4 hoursHalf-life (subcutaneous), 30-60 minutes (intranasal); longer for depot formulation (28-40 days)
~1%Bioavailability (oral); ~10-15% (intranasal); ~95% (subcutaneous)
1239.4Molecular weight, g/mol

Molecular formula

C60H86N16O13

CAS number
57773-65-6
PubChem
50225
Developed · 1983
Hoechst AG Research Team, Hoechst AG (now Sanofi)

Amino acid sequence

pGlu-His-Trp-Ser-Tyr-D-Ser-Leu-Arg-Pro-NHEt

Hormone SuppressionReversible hormone suppression after treatment stops

9.0

Cancer ManagementSuppresses testosterone to near-castrate levels for prostate cancer management

8.6

Fertility SupportImproves fertility outcomes when combined with IVF protocols

8.3

Ratings out of 10.

200 – 500mcg

Every documented dose level

PhaseDoseFrequencyRoute
First 7 days500 mcgEvery 8 hours (3 times daily)Subcutaneous
Ongoing maintenance200 mcgOnce dailySubcutaneous
Ongoing maintenance400 mcg (2 sprays per nostril)3 times daily (1,200 mcg/day)Intranasal
Long-term6.3 mgOnce every 2 monthsImplant
Long-term9.45 mgOnce every 3 monthsImplant
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for managing advanced prostate cancer & treating endometriosis and reducing associated pain

Best for

  • Managing advanced prostate cancer

    Buserelin is particularly well-suited for individuals focused on managing advanced prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Treating endometriosis and reducing associated pain

    Buserelin is particularly well-suited for individuals focused on treating endometriosis and reducing associated pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Optimizing ovarian response during fertility treatments

    Buserelin is particularly well-suited for individuals focused on optimizing ovarian response during fertility treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for hormone support supportConsult your healthcare provider for alternatives to Buserelin based on your specific needs and medical history
Alternative hormone-supporting peptidesKisspeptin-10GonadorelinPT-141 (Bremelanotide)
Non-peptide hormone supportClomiphene citrateAnastrozoleLifestyle modifications (sleep, exercise)

Do not use if

  • Pregnancy or breastfeeding
  • Hypersensitivity to GnRH agonists
  • Certain bone diseases when long-term use is planned

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Buserelin use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Buserelin with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Buserelin injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

Emergency signs first, then what this page and MedlinePlus say.

Buserelin is a GnRH agonist approved in Canada and Europe (not in the US), with safety data from Phase 3 trials and decades of clinical use, but carries well-documented risks from intentional testosterone/estrogen suppression.

The initial testosterone flare (first 2-3 weeks) can worsen prostate cancer symptoms and cause tumor flare pain in 10-20% of patients. Long-term use causes bone density loss of 2-3% annually, with vertebral fractures in 10-20% of long-term users.

Cardiovascular risks include increased MI and stroke in men over 65. Hot flashes affect 40-80%, erectile dysfunction is nearly universal, and liver enzyme elevations occur in 5%. Nasal spray formulation causes local irritation in 20-30% of users.

Buserelin was studied through Phase 3 clinical trials before approval in Canada and Europe (it has never been FDA approved), with decades of post-market pharmacovigilance data.

The flare phenomenon, bone loss, cardiovascular effects, and endocrine complications are well-characterized from long-term studies spanning over 30 years.

Comparative safety data with GnRH antagonists demonstrates buserelin's disadvantage regarding initial flare effect but similar long-term side effect profiles.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Buserelin
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Buserelin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeAnti-androgens (like bicalutamide) for prostate cancer—provides additional tumor control — May be used together under medical guidance.
  • SafeGonadotropins during IVF—enhances ovarian response and timing — May be used together under medical guidance.
  • SafeNSAIDs—helps manage pain and inflammation from endometriosis — May be used together under medical guidance.

With medications

  • CautionOther GnRH agonists—redundant and increases side effects — Use with caution—discuss with your healthcare provider.
  • CautionAlcohol in excess—may worsen hot flashes and mood changes — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Buserelin. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Strong human trials

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

Not FDA approved; no buserelin application in Drugs@FDA

Approved in Canada as SUPREFACT for advanced prostate cancer (injection and nasal solution) and endometriosis (nasal solution).

Onset of effects

Moderate

(1-2 weeks)


How it works

Buserelin is a GnRH agonist that first stimulates hormone release, then shuts down the whole system.

For endometriosis, this lowers estrogen dramatically, reducing tissue growth and pain. Available as injections or nasal spray for flexibility.

The deeper mechanism

Buserelin is a nonapeptide GnRH agonist with D-serine substitution at position 6. Initial agonistic activity causes FSH/LH release (flare, 7-14 days), followed by receptor desensitization and downregulation, achieving 90%+ suppression of testosterone and estrogen within 3-4 weeks.


Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Buserelin over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

31 registered studies, none currently enrolling.

31registered studies
0recruiting now
24phase 3 or 4
10with published results

By phase

Phase 3

13

Phase 4

11

Phase 1/2

2

Phase 1

2

No phase

3

A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.

What kind of research

Gave the drug

31

Records only

0

About 14,723 people took part in the studies that actually administered Buserelin. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.


Most recent

  • 2022-502634-52-00 Temporarily Halted280 enrolled

    UTN-01-2022

    Friedrich-Schiller-Universitaet Jena

  • NCT05567731 Completed30 enrolled

    Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve

    Tanta University

  • NCT05050084 Phase 3Active Not Recruiting2,050 enrolled

    Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

    NRG Oncology

See all 31 trials for Buserelin

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Buserelin is named as an intervention; studies that only mention it in passing are not.

How quickly does buserelin work?

You'll see some effects within 1-2 weeks, but full benefits take 4-6 weeks. For fertility, timing is precise—ovulation is prevented within days. For cancer, it takes several weeks to see tumor response.

Is buserelin reversible?

Yes! Once you stop taking it, your hormone levels return to normal within 4-8 weeks. Sexual function, mood, and energy improve as hormones bounce back.

Does buserelin hurt when injected?

Most people say the injection is a quick pinch, similar to other shots. Some experience minor bruising or redness at the injection site. Your doctor can show you proper injection technique to minimize discomfort.

Can I use buserelin if I want kids later?

For men with prostate cancer: fertility may be affected, but hormones usually recover after treatment stops. For women with endometriosis: buserelin actually improves fertility by reducing pain and improving egg quality during IVF. Talk to your doctor about your specific situation.

What about the nasal spray—does it work as well as injections?

Yes, the nasal spray works just as well if you use it correctly. You need to spray more frequently (usually 3 times per day), but hormone suppression is equally effective. Some people prefer it because there are no needles.

Will my hair fall out?

Hair loss is not a common side effect of buserelin. You might notice some thinning due to hormone suppression, but it's usually temporary and mild compared to chemotherapy.

How long can I take buserelin?

For endometriosis, doctors typically limit it to 6-12 months due to bone loss risk. For prostate cancer, you might take it indefinitely. For fertility, it's only a few weeks. Your doctor will determine what's safe for your situation.

Is buserelin available in the United States?

Not under the brand name Suprefact. However, similar GnRH agonists like leuprolide (Lupron) and goserelin (Zoladex) are available in the US and work similarly.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Buserelin, on one page.

Buserelin dosing protocol

Medical disclaimer

Buserelin is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

200 – 500 mcg Every 8 hours (3 times daily) or once daily · onset 1-2 weeks
Open the Buserelin calculatorBuserelin calculator